Analysts’ Weekly Ratings Updates for Boston Scientific (BSX)

Several analysts have recently updated their ratings and price targets for Boston Scientific (NYSE: BSX):

• 7/31/2026 – Boston Scientific had its “hold” rating reaffirmed by Argus.
• 7/30/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $85.00 to $70.00. They now have an “outperform” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by UBS Group AG from $74.00 to $67.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $60.00 price target on the stock.
• 7/30/2026 – Boston Scientific was given a new $56.00 price target by Robert W. Baird.
• 7/30/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $70.00 to $66.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $55.00 to $50.00. They now have an “equal weight” rating on the stock.
• 7/30/2026 – Boston Scientific was given a new $60.00 price target by Leerink Partners.
• 7/30/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $70.00 to $61.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $57.00 price target on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by TD Cowen from $61.00 to $56.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $62.00 to $57.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Boston Scientific was given a new $60.00 price target by Stifel Nicolaus.
• 7/29/2026 – Boston Scientific had its price target lowered by BTIG Research from $65.00 to $60.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/27/2026 – Boston Scientific had its price target lowered by Oppenheimer Holdings, Inc. from $90.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/25/2026 – Boston Scientific was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $64.00 to $62.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Boston Scientific had its price target lowered by Mizuho from $90.00 to $70.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $100.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $77.00 to $57.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Boston Scientific was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 7/6/2026 – Boston Scientific was given a new $65.00 price target by Evercore Inc.
• 6/25/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $75.00 to $65.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Boston Scientific had its price target lowered by Jefferies Financial Group Inc. from $100.00 to $67.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Boston Scientific had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 6/12/2026 – Boston Scientific had its “overweight” rating reaffirmed by Piper Sandler. They now have a $65.00 price target on the stock.
• 6/5/2026 – Boston Scientific was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/4/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $85.00 to $64.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Boston Scientific had its price target lowered by BTIG Research from $80.00 to $65.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $71.00 to $70.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.